指南与共识神经康复

抗凝患者肢体痉挛肉毒毒素治疗的德尔菲共识声明

A Delphi-Based Consensus Statement on the Management of Anticoagulated Patients With Botulinum Toxin for Limb Spasticity.
指南 / 共识 · Arch Phys Med Rehabil · 2018-05-24

该共识采用德尔菲法,由39名加拿大医师参与多问题电子调查,就抗凝患者接受A型肉毒毒素(BoNTA)肌内注射治疗肢体痉挛的考虑事项达成共识,协议水平≥75%即为达成共识。共识涉及注射不应因抗凝而取消、深部腿肌群注射的针具与INR要求、DOACs相关出血担忧及剂量调整等问题。

要点

  • 抗凝患者不应因抗凝而取消BoNTA注射,无论注射哪块肌肉。
  • 注射深部腿肌群时应使用25G或更小针头,且INR应≤3.5。
  • DOACs的出血担忧应与华法林(INR在治疗范围时)相同,且不应为降低出血风险而调整DOACs剂量或给药时间。

核心结论

  • 该共识为医师在抗凝患者中注射BoNTA治疗痉挛提供了考虑框架,但并非严格指南或决策步骤。

研究设计与样本

  • 采用德尔菲法,通过多问题电子调查对39名使用BoNTA注射治疗痉挛的加拿大医师进行共识调查,协议水平≥75%即达成共识。

主要发现

  • 共识认为抗凝患者不应因抗凝而取消BoNTA注射,无论注射肌肉。
  • 共识认为注射深部腿肌群时应使用25G或更小针头,且INR应≤3.5。
  • 共识认为若存在INR波动史、近期出血、过度或新发瘀斑等临床担忧,注射深部肌群时应考虑当日即时检验或前2-3天内的INR值。
  • 共识认为使用DOACs时的出血担忧应与华法林(INR在治疗范围时)相同。
  • 共识认为不应为在BoNTA注射前降低出血风险而调整DOACs的剂量和给药时间。

关键数值与推荐

  • 共识达成标准为每个问题的协议水平≥75%。
  • 注射深部腿肌群时INR应≤3.5,并使用25G或更小针头。
  • 存在INR波动史、近期出血、过度或新发瘀斑等临床担忧时,应考虑当日即时检验或前2-3天内的INR值。

临床怎么用

  • 抗凝患者不应因抗凝而取消BoNTA注射,注射深部腿肌群时选用25G或更小针头并确保INR≤3.5。
  • 使用DOACs时出血担忧与华法林(INR在治疗范围时)相同,不应为降低出血风险而调整DOACs剂量或给药时间。
  • 存在INR波动史、近期出血、过度或新发瘀斑等临床担忧时,注射深部肌群前应考虑当日即时检验或前2-3天内的INR值。

局限性

  • 该共识声明并非严格指南或决策步骤,而是在文献缺乏证据的情况下为形成共同理解所做的努力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To create a consensus statement on the considerations for treatment of anticoagulated patients with botulinum toxin A (BoNTA) intramuscular injections for limb spasticity. DESIGN: We used the Delphi method. SETTING: A multiquestion electronic survey. PARTICIPANTS: Canadian physicians (N=39) who use BoNTA injections for spasticity management in their practice. INTERVENTIONS: After the survey was sent, there were e-mail discussions to facilitate an understanding of the issues underlying the responses. Consensus for each question was reached when agreement level was ≥75%. MAIN OUTCOME MEASURES: Not applicable. RESULTS: When injecting BoNTA in anticoagulated patients: (1) BoNTA injections should not be withheld regardless of muscles injected; (2) a 25G or smaller size needle should be used when injecting into the deep leg compartment muscles; (3) international normalized ratio (INR) level should be ≤3.5 when injecting the deep leg compartment muscles; (4) if there are clinical concerns such as history of a fluctuating INR, recent bleeding, excessive or new bruising, then an INR value on the day of injection with point-of-care testing or within the preceding 2-3 days should be taken into consideration when injecting deep compartment muscles; (5) the concern regarding bleeding when using direct oral anticoagulants (DOACs) should be the same as with warfarin (when INR is in the therapeutic range); (6) the dose and scheduling of DOACs should not be altered for the purpose of minimizing the risk of bleeding prior to BoNTA injections. CONCLUSIONS: These consensus statements provide a framework for physicians to consider when injecting BoNTA for spasticity in anticoagulated patients. These consensus statements are not strict guidelines or decision-making steps, but rather an effort to generate common understanding in the absence of evidence in the literature.

来源:Arch Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Boulias C, Ismail F, Phadke CP, et al. A Delphi-Based Consensus Statement on the Management of Anticoagulated Patients With Botulinum Toxin for Limb Spasticity. Arch Phys Med Rehabil. 2018. PMID: 29803825. doi:10.1016/j.apmr.2018.04.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。